Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122575 | 0.85 | ADORA3 (0.66) | ADORA2AADORA2BNT5EADORA3ADORA1 | |
| SCHEMBL9762773 | 0.82 | ADORA2A (0.72) | ADORA2AADORA2B | |
| SCHEMBL9762789 | 0.82 | ADORA2A (0.72) | ADORA2AADORA2B | |
| SCHEMBL16600157 | 0.81 | LMNA (0.72) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL7453847 | 0.80 | ADORA2A (0.64) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL24359132 | 0.78 | LMNA (0.78) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL440329 | 0.78 | LMNA (0.78) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL972926 | 0.78 | LMNA (0.78) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL16579288 | 0.78 | LMNA (0.78) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL22559823 | 0.78 | LMNA (0.78) | ADORA2AADORA2BLMNANT5EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050226-A1 | Dopamine analog amide | SHASHOUA VICTOR E (US) | 2003-03-13 | — | — | US | disclosed |
| US-6407137-B2 | A PRODRUG COMPOUND CAPABLE OF FACILITATING THE PASSAGE OF A DRUG ACROSS THE BLOOD BRAIN BARRIER COMPRISING A FATTY ACID COUPLED TO A DRUG TO FORM A PRODRUG | PROTARGA, INC. | 2002-06-18 | — | — | US | disclosed |
| US-20010056116-A1 | Dopamine analog amide | LUITPOLD PHARMACEUTICALS, INC. | 2001-12-27 | — | — | US | disclosed |
| US-6258836-B1 | FATTY ACID COUPLED TO ANTIAIDS SUBSTANCE, ANTIBIOTIC, CHOLINERGIC AGONIST AND OTHER USES FOR PASSING THE BLOOD BRAIN BARRIER | PROTARGA, INC. | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056116-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | ADORA2A 84/4885ADORA2B 113/4885LMNA 4166/4885 |
| US-20030050226-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | ADORA2A 84/4885ADORA2B 113/4885LMNA 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.